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Although this is a non-themed issue, the focus of the papers and reviews collected in 
Genomics, Society and Policy 5.1 clearly tend to converge towards a common theme 
that, apparently, has become a major and urgent item for reflection and deliberation 
within our field, namely the way in which genomics research agendas tend to evolve, 
notably the extent to which they allow themselves be targeted towards addressing 
urgent societal issues as well as the extent to which they allow “upstream” 
involvement and participation from future stakeholders representing various sections 
of society. 
  
Helen Wallace takes up this theme from a historical perspective, reflecting in a 
detailed manner on the way in which the tobacco industry, through research funded by 
the Council for Tobacco Research (CTR), invested in the identification of oncogenes 
responsible for causing lung cancer, so as to downplay the more general causal link 
between lung cancer and smoking habits, focusing attention instead on a minority of 
smokers, carriers of a genetic disposition that made them more prone than others to 
developing cancer. This theme (the identification of a sub-section of smokers 
exceptionally susceptible to developing cancer and other health problems) was later 
taken up by the Human Genome Project. Wallace concludes that during the past 
decades, major research investments have been conducted in accordance with agenda 
priorities of tobacco companies. She argues that in the future more democratic and 
transparent decisions about research funding priorities are required. 
  
The paper by Bovenberg et al focuses on the governance of biobank research and how 
this type of research may further develop in the future. Biobanks are uniquely 
positioned when it comes to translating population-based health data into 
“personalized” bioinformation. In order to explore the future development of this 
research, a fictional court case is designed, in which a number of emerging ethical and 
legal issues are addressed. In the paper by Fortin and Knoppers, a similar issue is 
addressed, this time focusing on the research into the relationship between asbestos 
exposure and lung cancer. The authors argue that although this research has clearly 
improved the health perspectives of workers in construction practices, such research 
could not have been conducted in the normative landscape of the present, notably 
because of restrictions on secondary uses of bioinformation (the deployment of 
databank information for other questions that those initially addressed). This raises the 
question whether current regulations (current practices of governance of research 
infrastructures such as databanks) are optimal when it comes to addressing the 
emerging promises and challenges of population research. Finally, two other 
contributions (by Patra et al and Suda et al) address similar issues but in a different 
socio-cultural context, namely in India and Japan. Patra et al discuss some of the 
impediments or hindrances encountered while exercising the principle of informed 
consent in the context of genetic and genomics research among the tribal and rural 
caste communities in India (hindrances such as illiteracy, poverty, paternalistic 
attitudes, sociocultural barriers, ineffective regulatory mechanism and procedural 
inconsistency, among others). The authors conclude that, although the sociopolitical 
landscape in India contains major challenges for the implementation of informed 
consent in genomics research, it is nonetheless important that informed consent 
remains part of the normative infrastructure for governing future research 
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developments and agenda-setting in the area. In the paper by Suda et al it is indicated 
that, although Japan made a major contribution to large-scale genomics research 
activities, such as the sequencing of the human genome, less than 1% of the research 
budget involved has been devoted to ELSI or ELSA research. It should not come as a 
surprise, therefore, that, whereas in many other countries public engagement in 
science and technology has grown in importance as developments in science and 
technology make increasingly significant impacts on people’s lives, public 
involvement in Japan is rather sparse. This is analysed in the context of the 
International Haplotype Mapping (HapMap) Project as a case study. 
 
The common theme of agenda-building and societal involvement is present in our 
book reviews section as well. Bart Penders reviews a fascinating thesis by Niki 
Vermeulen on the emergence of big science in biology: the projectification of biology 
through the implementation of large-scale research endeavours, encompassing all 
zones of life, from oceanography down to virology. Marli Huijer reviews Paul 
Rabinow’s recent monograph Marking Time, a reflection on how a philosophical 
anthropologist should respond to the acceleration of pace as a key feature of 
contemporary research agenda’s in the life sciences (apparently by becoming overtly 
productive and prolific at an equally high pace himself). Last but not least, Ursula 
Naue reviews Limits to Governance, reflecting the output of genomics and society 
research by the ESRC Innogen Centre at Edinburgh. The volume presents a 
multifaceted approach to governance of the life sciences. Its main objective is to 
provide a critique to the new governance agendas for science and innovation as 
emerging in the context of the life sciences, notably genomics. In her review Naue 
notably addresses some of the conceptual issues involved as well as the development 
of “a creative set of alternatives” for current governance practices as a task for the 
future. 
  
Thus, this GSP issue reflects in a lively manner how the ELSA genomics research 
community is taking stock of the outcomes of our work so far, notably concerning 
some of the major issues (governance of “big” life science research, secondary uses of 
bioinformation, informed consent procedures in a global context etc.) that need to be 
taken up again in the context of emerging life sciences agenda’s of the near future.  
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